Zilucoplan
Also known as: RA1010, RA101495, Zilbrysq, zilucoplan
Source Zilucoplan at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Zilucoplan is a subcutaneously administered, 15‑residue macrocyclic peptide that selectively inhibits complement C5. It is in late‑stage clinical development for generalized myasthenia gravis and other complement‑mediated disorders.
Mechanism of Action
Binds complement component C5, blocking its cleavage to C5a and C5b and thereby inhibiting formation of the membrane attack complex.
Routes of Administration
Goals & Uses
- Generalized Myasthenia GravisAutoimmune Neuromuscular DiseaseModerate
- Complement inhibitionImmunology/inflammationHigh
- Reduction of neuromuscular junction damageNeuroprotectionHigh
- Treatment of generalized myasthenia gravis (gMG)Neuromuscular DiseaseHigh
Contraindications
- Lack of meningococcal vaccination prior to initiationInfection PreventionHigh
- Unresolved Neisseria meningitidis infectionInfectious DiseaseHigh
- Known hypersensitivity to Zilucoplan or any excipientAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Serious infections (meningococcal)InfectionRare
- Upper respiratory tract infectionInfectiousUncommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Live vaccinesModerate
- Other immunosuppressantsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Patients with active systemic infectionsInfectious DiseaseRelative
- Pregnant or breastfeeding womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalUnder EMA review; no marketing authorization.
- United StatesInvestigationalPhase 3 trials ongoing; not FDA‑approved.
- United KingdomInvestigationalMHRA has granted clinical trial permission only.
As of 2024 the product remains in Phase 3 trials; no regulatory approval in the US, EU, or UK.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Zilucoplan?
Zilucoplan is a subcutaneously administered, 15‑residue macrocyclic peptide that selectively inhibits complement C5. It is in late‑stage clinical development for generalized myasthenia gravis and other complement‑mediated disorders.
What is Zilucoplan used for?
Zilucoplan is educationally associated with: Generalized Myasthenia Gravis, Complement inhibition, Reduction of neuromuscular junction damage, Treatment of generalized myasthenia gravis (gMG). Educational only — not medical advice.
How is Zilucoplan administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Zilucoplan?
Reported adverse effects include: Injection site reactions, Headache, Serious infections (meningococcal), Upper respiratory tract infection, Diarrhea, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Zilucoplan?
Recorded contraindications: Lack of meningococcal vaccination prior to initiation, Unresolved Neisseria meningitidis infection, Known hypersensitivity to Zilucoplan or any excipient. Consult a qualified clinician before use.